Eurofins CDMO Alphora Inc. Launches Biologics Initiative Focusing on mAbs and Therapeutic Proteins
Eurofins CDMO Alphora Inc., based in Mississauga, Canada, is excited to announce the launch of its Biologics initiative, aimed at diversifying and expanding its presence in the contract development and manufacturing industry in North America. The multiphase initiative will establish a facility at the Sheridan Research Park campus in Mississauga, Ontario. The first phase, scheduled for completion by December 2023, will feature a 3,300 square foot pilot scale facility dedicated to mammalian cell culture (mAbs) and therapeutic proteins.
Supported by a $2.5 million grant from the Ontario Government through the Ontario Together Fund (OTF), this $6.3 million investment by Eurofins CDMO Alphora signifies a significant commitment to advancing biologics development and manufacturing capabilities.
Comprehensive Biologics Offerings
The Biologics initiative will encompass a wide range of services, including analytical, upstream, and downstream development, process design, gap analysis, process scale-up, bioassays, and cGMP quality documentation. The upstream processing laboratories will be equipped with cutting-edge technology capable of accommodating various mammalian and avian cell lines, enabling flexibility in batch sizes. With a team of experienced scientists in bioprocess engineering, Eurofins CDMO Alphora will prioritize speed-to-market by utilizing bench-scale technology and Design of Experiments (DoE) to develop effective scale-up strategies, minimizing costs and resources.
Enhancing Efficiency and Safety
The downstream processing equipment will facilitate the development of robust, economical, and scalable processes in line with Quality by Design (QbD) principles. The analytical laboratory will offer a wide range of bio-analytical assays for cGMP and non-cGMP applications, supporting process and drug candidate characterization. Additionally, Eurofins CDMO Alphora's expertise in linker and warhead development and manufacturing will support clients with antibody drug conjugate candidates.
By leveraging their expertise in small molecule drug development, production, and analytical development since 2003, Eurofins CDMO Alphora aims to provide clients with an integrated suite of complementary technologies. This expansion will strengthen Ontario's supply chains and contribute to the growth of Canada's biologics industry.
For more information, please visit: www.eurofins.com/cdmo
Hot Take: The Impact of Eurofins CDMO Alphora's Biologics Initiative on New Businesses
The launch of Eurofins CDMO Alphora's Biologics initiative could have significant implications for new businesses, particularly those in the biotechnology and pharmaceutical sectors. This initiative, which focuses on the development and manufacturing of monoclonal antibodies (mAbs) and therapeutic proteins, represents a significant investment in the biologics industry in North America.
For new businesses, this initiative could provide valuable opportunities for collaboration and partnership. The comprehensive range of services offered, including analytical, upstream, and downstream development, process design, gap analysis, process scale-up, bioassays, and cGMP quality documentation, could provide new businesses with access to cutting-edge technologies and expertise.
Furthermore, Eurofins CDMO Alphora's commitment to speed-to-market could have a positive impact on new businesses. By utilizing bench-scale technology and Design of Experiments (DoE) to develop effective scale-up strategies, Eurofins CDMO Alphora could help new businesses bring their products to market more quickly and cost-effectively.
However, new businesses must also be prepared to navigate the challenges associated with the biologics industry, including the need for robust, economical, and scalable processes and the management of complex supply chains. The success of Eurofins CDMO Alphora's Biologics initiative will depend on its ability to address these challenges and deliver on its promises.